Turning Point Brands Stock Plummets 15.5% Amid FDA Nicotine Pouch Concerns

Shares of Turning Point Brands (NYSE: TPB) fell 15.5% this week, according to S&P Global Market Intelligence data, as concerns over regulatory hurdles for nicotine pouches weighed on investor sentiment. The company, which operates in the consumer discretionary sector with a diverse portfolio including tobacco rolling papers, chewing tobacco, and nicotine pouches, faces potential challenges from the Food and Drug Administration (FDA). Recent reports indicate the FDA is cautious about approving new nicotine pouch types, citing safety concerns for children. This regulatory uncertainty has sparked fears of a slowdown in the growth of the nicotine pouch segment, a key driver for Turning Point Brands. The company's nicotine pouch brand, Fre, has been a significant contributor to its revenue, with the segment's revenue surging 266% year-over-year last quarter to $41.3 million, representing 34% of total company revenues. Guidance for 2026 projects net revenue of $180 million to $190 million for the category. However, the stock has now declined 50% from its previous highs, raising questions about the sustainability of its growth trajectory. The FDA's potential regulatory actions could mirror the impact seen during the vaping crisis a decade ago, which led to stricter controls and market corrections. Investors are now evaluating whether the current stock price, with a market cap of $1.3 billion, reflects a buying opportunity or a deeper structural risk for the company's future in the evolving nicotine market.